Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing. The ...

On May 13, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi) tablets in combination with ...

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy. Oncology nurses have a new therapeutic option ...

Both pre- and post-evidence–based practice change occlusion rates were low with relation to anticipated rates among hospitalized adult patients with cancer.

A landmark study led by researchers at Keck Medicine of USC, recently published in the Journal of Vascular Surgery, indicates ...

MD Anderson’s trial uses psilocybin to help oncology patients overcome anxiety and depression during maintenance therapy. For ...

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects. On May 1, the FDA granted approval to ...

What Efficacy Data Back It Up? The multicenter, single-arm, open-label expansion cohort phase 1/2 KRYSTAL-1 trial (NCT03785249), upon which the combination’s approval was based, evaluated adagrasib as ...

FDA approves vepdegestrant for ER-positive, HER2-negative breast cancer. Learn key efficacy data, safety risks, and nursing ...

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular ...

Oncology nurses play a critical role in the success of clinical trials, balancing patient care, safety and research ...